Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PCVX Stock Forecast 2026-2027
$56.04
Current Price
$8.09B
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PCVX Price Targets
+190.9%
To High Target of $163.00
+96.3%
To Median Target of $110.00
+19.6%
To Low Target of $67.00
PCVX Price Momentum
-3.7%
1 Week Change
+10.6%
1 Month Change
+50.0%
1 Year Change
+21.5%
Year-to-Date Change
-13.8%
From 52W High of $65.00
+92.7%
From 52W Low of $29.08
📊 TOP ANALYST CALLS
Did PCVX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vaxcyte is one of their latest high-conviction picks.
Latest PCVX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PCVX has a bullish consensus with a median price target of $110.00 (ranging from $67.00 to $163.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $56.04, the median forecast implies a 96.3% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PCVX Analyst Ratings
10
Buy
1
Hold
0
Sell
PCVX Price Target Range
Low
$67.00
Average
$110.00
High
$163.00
Current: $56.04
Latest PCVX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PCVX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 26, 2026 | BTIG | Thomas Shrader | Buy | Maintains | $89.00 |
| Feb 2, 2026 | Guggenheim | Buy | Reiterates | $N/A | |
| Nov 10, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Oct 16, 2025 | BTIG | Buy | Maintains | $N/A | |
| Sep 12, 2025 | Goldman Sachs | Neutral | Initiates | $N/A | |
| Apr 22, 2025 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Apr 8, 2025 | Needham | Buy | Reiterates | $N/A | |
| Apr 1, 2025 | Goldman Sachs | Buy | Maintains | $N/A | |
| Apr 1, 2025 | B of A Securities | Buy | Maintains | $N/A | |
| Apr 1, 2025 | Needham | Buy | Maintains | $N/A | |
| Mar 12, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Feb 26, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Feb 26, 2025 | Needham | Buy | Reiterates | $N/A | |
| Feb 24, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Feb 11, 2025 | Needham | Buy | Reiterates | $N/A | |
| Dec 24, 2024 | BTIG | Buy | Reiterates | $N/A | |
| Dec 20, 2024 | Goldman Sachs | Buy | Initiates | $N/A | |
| Nov 6, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Nov 6, 2024 | Needham | Buy | Reiterates | $N/A | |
| Sep 10, 2024 | Mizuho | Outperform | Maintains | $N/A |
Vaxcyte, Inc. (PCVX) Competitors
The following stocks are similar to Vaxcyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vaxcyte, Inc. (PCVX) Financial Data
Vaxcyte, Inc. has a market capitalization of $8.09B with a P/E ratio of -10.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -30.6%.
Valuation Metrics
Market Cap
$8.09B
Enterprise Value
$6.57B
P/E Ratio
-10.1x
PEG Ratio
-0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+21.5%
Current Ratio
7.5x
Debt/Equity
3.9x
ROE
-30.6%
ROA
-20.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vaxcyte, Inc. (PCVX) Business Model
About Vaxcyte, Inc.
What They Do
Develops innovative vaccines for infectious diseases.
Business Model
The company utilizes a proprietary cell-free protein synthesis platform to create safer and more effective vaccines, generating revenue through partnerships, grants, and potential product sales in the pharmaceutical industry. By focusing on diseases with high unmet needs, Vaxcyte positions itself to capture market demand and contribute to public health.
Additional Information
Vaxcyte’s technology aims to enhance vaccine design and production efficiency, addressing significant global health challenges and improving public health outcomes. The company's innovative approach could redefine standards in vaccine development, making it a key player in the biotechnology market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
507
CEO
Mr. Grant E. Pickering M.B.A.
Country
United States
IPO Year
2020
Website
vaxcyte.comVaxcyte, Inc. (PCVX) Latest News & Analysis
Latest News
Quick Summary
Vaxcyte, Inc. (Nasdaq: PCVX) will participate in investor conferences and host one-on-one meetings, as announced on July 8, 2026.
Why It Matters
Vaxcyte's participation in investor conferences may signal strategic growth opportunities and increased visibility, potentially influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A first-in-human study is underway for VAX-A1, a vaccine candidate aimed at providing broad protection against Group A Streptococcus diseases.
Why It Matters
The VAX-A1 study signals potential for a breakthrough vaccine in infectious disease, which could lead to significant market opportunities and revenue growth for the developing company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The health care sector has identified oversold stocks, indicating potential investment opportunities in undervalued companies.
Why It Matters
Oversold stocks in health care indicate potential undervalued investments, presenting opportunities for gains as market correction may lead to price increases.
Source: Benzinga
Market Sentiment:
Positive
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2 months ago
Quick Summary
Vaxcyte, Inc. (PCVX) presented at the Bank of America Global Healthcare Conference, showcasing developments and strategies for investors.
Why It Matters
Vaxcyte's presentation at a major healthcare conference can signal potential growth and developments, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Enrollment is complete for the OPUS-1, OPUS-2, and OPUS-3 Phase 3 trials testing VAX-31, aimed at preventing invasive pneumococcal disease and pneumonia in adults.
Why It Matters
Completion of enrollment in Phase 3 trials for VAX-31 signals progress in vaccine development, impacting potential market approval and future revenue for the company involved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Vaxcyte is transitioning to a commercial vaccine platform, advancing its 31-valent VAX-31 in pivotal trials. It has $2.4B in cash and a ready manufacturing facility for late-stage development.
Why It Matters
Vaxcyte's transition to a commercial vaccine platform and strong financial position suggest potential for significant revenue growth and competitive advantage, attracting investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About PCVX Stock
What is Vaxcyte, Inc.'s (PCVX) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Vaxcyte, Inc. (PCVX) has a median price target of $110.00. The highest price target is $163.00 and the lowest is $67.00.
Is PCVX stock a good investment in 2027?
According to current analyst ratings, PCVX has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $56.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PCVX stock?
Wall Street analysts predict PCVX stock could reach $110.00 in the next 12 months. This represents a 96.3% increase from the current price of $56.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vaxcyte, Inc.'s business model?
The company utilizes a proprietary cell-free protein synthesis platform to create safer and more effective vaccines, generating revenue through partnerships, grants, and potential product sales in the pharmaceutical industry. By focusing on diseases with high unmet needs, Vaxcyte positions itself to capture market demand and contribute to public health.
What is the highest forecasted price for PCVX Vaxcyte, Inc.?
The highest price target for PCVX is $163.00 from at , which represents a 190.9% increase from the current price of $56.04.
What is the lowest forecasted price for PCVX Vaxcyte, Inc.?
The lowest price target for PCVX is $67.00 from at , which represents a 19.6% increase from the current price of $56.04.
What is the overall PCVX consensus from analysts for Vaxcyte, Inc.?
The overall analyst consensus for PCVX is bullish. Out of 2 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $110.00.
How accurate are PCVX stock price projections?
Stock price projections, including those for Vaxcyte, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 5:09 PM UTC